IL6 and prostate carcinoma: It is noteworthy that, as in early-stage breast cancer, IL-6 functions as an inhibitor of cancer cell growth in benign prostate hyperplasia (Degeorges et al, 1996), but is correlated with a poor survival in stage-D prostate cancer (Nakashima et al, 2000).